ES2164018A1 - Lithium salt based formulation of human syncytial respiratory virus medicine has the general formula ALi(n) where A is the salt anion and n equals the number of negative charges of the anion - Google Patents

Lithium salt based formulation of human syncytial respiratory virus medicine has the general formula ALi(n) where A is the salt anion and n equals the number of negative charges of the anion

Info

Publication number
ES2164018A1
ES2164018A1 ES200001347A ES200001347A ES2164018A1 ES 2164018 A1 ES2164018 A1 ES 2164018A1 ES 200001347 A ES200001347 A ES 200001347A ES 200001347 A ES200001347 A ES 200001347A ES 2164018 A1 ES2164018 A1 ES 2164018A1
Authority
ES
Spain
Prior art keywords
anion
equals
general formula
negative charges
based formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200001347A
Other languages
Spanish (es)
Other versions
ES2164018B1 (en
Inventor
Vico Nieves Maria Villanueva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Salud Carlos III
Original Assignee
Instituto de Salud Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Salud Carlos III filed Critical Instituto de Salud Carlos III
Priority to ES200001347A priority Critical patent/ES2164018B1/en
Publication of ES2164018A1 publication Critical patent/ES2164018A1/en
Application granted granted Critical
Publication of ES2164018B1 publication Critical patent/ES2164018B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Lithium salt based formulation of human syncytial respiratory virus medicine has the general formula ALi(n) where A is the salt anion and n equals the number of negative charges of the anion.
ES200001347A 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH) Expired - Fee Related ES2164018B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200001347A ES2164018B1 (en) 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001347A ES2164018B1 (en) 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Publications (2)

Publication Number Publication Date
ES2164018A1 true ES2164018A1 (en) 2002-02-01
ES2164018B1 ES2164018B1 (en) 2003-06-16

Family

ID=8493689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001347A Expired - Fee Related ES2164018B1 (en) 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Country Status (1)

Country Link
ES (1) ES2164018B1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135312A2 (en) * 1983-07-27 1985-03-27 Pharmaceuticals Limited Scotia Anti-viral compositions
ES2008767A6 (en) * 1987-11-13 1989-08-01 Medical Research Int Destruction of intra-and extra-cellular micro-organisms
EP0484112A2 (en) * 1990-10-31 1992-05-06 Scotia Holdings Plc Use of lithium in the treatment or prophylaxis of Molluscum contagiosum
ES2034326T3 (en) * 1987-09-22 1993-04-01 Atlantic Pharmaceutical Products Limited EXPERT COMPOSITION.
FR2715301A1 (en) * 1994-01-24 1995-07-28 Aromafarm Ltd Antiviral use of zinc and lithium ascorbate(s)
WO1998017288A1 (en) * 1996-10-22 1998-04-30 Scotia Holdings Plc Lithium containing medicament for combatting papilloma virus infections
EP0978289A1 (en) * 1998-07-29 2000-02-09 Aleksandr Ivanovic Iljin Virucide drug containing iodine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135312A2 (en) * 1983-07-27 1985-03-27 Pharmaceuticals Limited Scotia Anti-viral compositions
ES2034326T3 (en) * 1987-09-22 1993-04-01 Atlantic Pharmaceutical Products Limited EXPERT COMPOSITION.
ES2008767A6 (en) * 1987-11-13 1989-08-01 Medical Research Int Destruction of intra-and extra-cellular micro-organisms
EP0484112A2 (en) * 1990-10-31 1992-05-06 Scotia Holdings Plc Use of lithium in the treatment or prophylaxis of Molluscum contagiosum
FR2715301A1 (en) * 1994-01-24 1995-07-28 Aromafarm Ltd Antiviral use of zinc and lithium ascorbate(s)
WO1998017288A1 (en) * 1996-10-22 1998-04-30 Scotia Holdings Plc Lithium containing medicament for combatting papilloma virus infections
EP0978289A1 (en) * 1998-07-29 2000-02-09 Aleksandr Ivanovic Iljin Virucide drug containing iodine

Also Published As

Publication number Publication date
ES2164018B1 (en) 2003-06-16

Similar Documents

Publication Publication Date Title
NZ515392A (en) Respiratory syncytial virus replication inhibitors
YU57600A (en) Bicyclic hydroxamic acid derivatives
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
NO20065380L (en) Use of R - (+) - 2- (3-diisopropylamino-1-phenylpropyl) -4-hydroxymethylphenylisosbutyric acid hydrogen fumarate for the preparation of a medicament for the treatment of urinary incontinence and other spasmogenic diseases.
MX9201621A (en) USEFUL HETEROCICLIC AMINES IN THE THERAPY OF ASTHMA AND INFLAMMATION OF THE RESPIRATORY TRACT.
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
DE69420412D1 (en) THERAPEUTIC INHALATION PREPARATION
GB0105772D0 (en) Use
NZ526088A (en) Urea substituted imidazoquinoline ethers
MXPA04004601A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments.
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
NZ298769A (en) use of progesterone-antagonistic and anti-estrogen compounds in a single dose for female contraception
RS20070077A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflamatory diseases
JPS53118516A (en) Inactivation disinfectant of hepatitis-b virus
NO982989L (en) Use of inhibitors of the cellular Na + / H + exchanger (NHE) for the manufacture of a medicament for respiratory stimulation
ES8800161A1 (en) Quinolyl glycinamide derivatives, process for their preparation and their pharmaceutical use as psychotropes.
GB9108629D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
ES2164018A1 (en) Lithium salt based formulation of human syncytial respiratory virus medicine has the general formula ALi(n) where A is the salt anion and n equals the number of negative charges of the anion
EA200401303A1 (en) MEDICINES CONTAINING STEROIDS AND NEW ANTICHOLINERGIC MEANS
EE200200088A (en) Use of bis-sulfonamides in the manufacture of a medicament for the prevention or treatment of hyperlipidemia
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
JPS5396388A (en) Preparation of l-phenylalanine
AU2003281257A1 (en) A novel use of rapamycin and structural analogues thereof
AU1039601A (en) Medicaments for treatment of respiratory syncytial virus infections

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020201

Kind code of ref document: A1

Effective date: 20020201

FG2A Definitive protection

Ref document number: 2164018B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807